Solara Active Pharma Sciences vs Peers
- Market cap
- ₹3,120 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹466.34 – ₹874.40
Solara Active Pharma Sciences ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Solara Active Pharma Sciences. Its P/E of 22.5 compares with a peer median of 22.5.
Solara Active Pharma Sciences vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Solara Active Pharma Sciences | 647.70 | -1.10% | 3,120 | 22.5 | 2.85 | 14.5% | +18.5% |
| Solara Active Pharma Sciences | 647.70 | -1.10% | 3,120 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Solara Active Pharma Sciences peer comparison — frequently asked questions
Who are Solara Active Pharma Sciences' competitors?
Solara Active Pharma Sciences' listed peers in Drug Manufacturers - Specialty & Generic include Solara Active Pharma Sciences, ranked here by market capitalisation.
How does Solara Active Pharma Sciences' P/E compare with its peers?
Solara Active Pharma Sciences trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Solara Active Pharma Sciences' peers?
By market capitalisation, the largest company in the group is Solara Active Pharma Sciences at ₹3,120 crore, against ₹3,120 crore for Solara Active Pharma Sciences.
Same Data For Peers
Trade Solara Active Pharma Sciences With ATS
Track SOLARA live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.